Similarly, in our previous studies in a panel of cancer cell lines of eight different types of cancer, we noticed that after treatment with lapatinib (an inhibitor of EGFR and HER2), almost all HER2-amplified cancers show only a transient HER3 inactivation and HER3 is eventually re-phosphorylated over time [77]. This evidence concerns the gene ERBB3 and cancer.